Researchers report that BRD4 is emerging as a key regulator of STING expression in cancer cells, with downstream effects on innate immune signaling. In preclinical work, BET inhibition suppressed STING by targeting promoter and enhancer regions, weakening STING-driven responses that PARP inhibitors can trigger—raising potential combination-therapy constraints.